Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
11 Results for "
Dual-inhibition
" in MedChemExpress (MCE) Product Catalog:
Products (11)
11 Results for "Dual-inhibition" in MCE Product Catalog:
Cat. No.: HY-178360
CAS No.: 2966791-41-1
Research Areas:
NP1192 is a potent, selective PROTAC NAT10 degrader. NP1192 promotes NAT10 ubiquitination and degradation. NP1192 inhibits ac4C modification. NP1192 demonstrates dual inhibition of hypoxia-driven glycolysis and immunosuppression via NAT10/HIF-1α/PD-L1 axis disruption, achieving superior antitumor efficacy and synergizing with anti-PD-L1 both in vitro and in vivo. NP1192 can be used for ovarian, cervical, and glioblastoma cancer research .
Target:
Research Areas:
NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca 2+ inward flow .
Cat. No.: HY-179496
Target:
Research Areas:
ChE/GSK-3β-IN-1 (compound 18o) is a potent dual ChE/GSK-3β inhibitor. ChE/GSK-3β-IN-1 exhibits dual inhibition of AChE (IC50 = 1.7 μM), butyrylcholinesterase (BChE) (IC50 = 5.3 μM), and GSK-3β (IC50 = 5.7 μM). ChE/GSK-3β-IN-1 inhibits Aβ1-42 self-aggregation. ChE/GSK-3β-IN-1 can be used for Alzheimer’s disease (AD) research .
Cat. No.: HY-174338
Target:
Research Areas:
GPER/Bcl-2-IN-1 is a GPER/Bcl-2 inhibitor. GPER/Bcl-2-IN-1 can inhibit the proliferation and neurospheres formation of glioblastoma cells. GPER/Bcl-2-IN-1 can be used for the study of glioblastoma multiforme (GBM) .
Cat. No.: HY-163755
CAS No.: 2629960-35-4
Target:
Research Areas:
GPER activator 1 (compound 6-26) is a GPER-selective compound without cytotoxicity. GPER activator 1 exhibits dual inhibition of TNFα- and IL-6-induced inflammation .
Cat. No.: HY-143402
CAS No.: 2770804-58-3
Target:
Research Areas:
Topoisomerase I/II inhibitor 2 (compound 1a) is a potent Topoisomerase inhibitor (IC50= 9.82 μM on Huh7 cells and 6.83 μM on LM9 cells). Topoisomerase I/II inhibitor 2 has dual inhibition on DNA topoisomerase I/II, also can obviously reduce the growth of xenograft tumor in mice model. Topoisomerase I/II inhibitor 2 has the potential value in researching liver cancer .
Cat. No.: HY-183250
Target:
Research Areas:
eALM1137 is a mTOR inhibitor with an IC50 of 4.8 nM. eALM1137 mediates dual inhibition of the mTORC1 and mTORC2 signaling pathways, and inhibits DNA-PK (IC50=77 nM). eALM1137 exhibits antiproliferative and cytostatic activities, and induces G1 cell cycle arrest. eALM1137 is applicable to the research of glioblastoma multiforme .
Cat. No.: HY-181525
Research Areas:
Mito-DHH chloride is a mitochondria-targeted catechol-type diphenylhexatriene. Mito-DHH chloride rapidly accumulates in mitochondria and undergoes auto-oxidation in the alkaline mitochondrial matrix to generate ROS. Mito-DHH chloride triggers ROS-dependent reduction of ATP levels via dual inhibition of mitochondrial oxidative phosphorylation and glycolytic metabolism, and induces selective apoptosis in cancer cells. Mito-DHH chloride can be used in research related to lung cancer, liver cancer, malignant melanoma, and colon cancer .
Cat. No.: HY-179437
anti-HIV agent 1 (compound 10i) is a potent antiviral agent with anti-HIV activity (IC50 = 10.6 nM). anti-HIV agent 1 exhibits moderate to no inhibitory activity against RT mutant strains, but maintains their activity against wild-type viruses. anti-HIV agent 1 strongly shows dual inhibition of the viral attachment and reverse transcriptase phases of the viral life cycle. anti-HIV agent 1 can be used for HIV infection research .
Cat. No.: HY-184382
Target:
Research Areas:
α-Amylase-IN-15 is a dual inhibitor of α-amylase and α-glucosidase, with IC50 values of 6.7 μM and 18.55 μM, respectively, and a Ki value of 50.9 μM against α-amylase. α-Amylase-IN-15 binds to both free α-amylase and the enzyme-substrate complex. By inhibiting α-glucosidase, α-Amylase-IN-15 achieves dual inhibition of carbohydrate metabolic enzymes. α-Amylase-IN-15 can be used in the research of type 2 diabetes .
Cat. No.: HY-179581
CAS No.: 2962069-39-0
Target:
Research Areas:
SLC6A19-IN-4 is an allosteric-competitive and orally active B 0AT1 inhibitor. SLC6A19-IN-4 inhibits both human and mouse B 0AT1 with IC50 values of 513 nM and 295 nM, respectively. SLC6A19-IN-4 exhibits excellent metabolic stability. SLC6A19-IN-4 significantly increases urinary phenylalanine (Phe) excretion and reduces plasma Phe levels through dual inhibition of B 0AT1 in both the intestine (reducing absorption) and kidney (promoting excretion) in vivo. SLC6A19-IN-4 can be used for phenylketonuria (PKU) and other disorders involving SLC6-family transporters research .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
